{
    "clinical_study": {
        "@rank": "74044", 
        "acronym": "RILOMET-2", 
        "arm_group": [
            {
                "arm_group_label": "Rilotumumab", 
                "arm_group_type": "Experimental", 
                "description": "Rilotumumab plus Cisplatin and Capecitabine (CX)."
            }, 
            {
                "arm_group_label": "Rilotumumab-placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Rilotumumab-placebo plus Cisplatin and Capecitabine (CX)."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of\n      Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced\n      mesenchymal epithelial transition factor (MET)-positive gastric or gastroesophageal junction\n      adenocarcinoma (GEJ)."
        }, 
        "brief_title": "A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer", 
        "completion_date": {
            "#text": "October 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Pathologically confirmed unresectable locally advanced or metastatic gastric or GEJ\n             adenocarcinoma.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.\n\n          -  Tumor MET-positive by immunohistochemistry (IHC).\n\n          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n             criteria.\n\n          -  Male or female subject greater than or equal to 20 years of age at the time of\n             informed consent.\n\n        Key Exclusion Criteria:\n\n          -  Human epidermal growth factor receptor 2 (HER2)-overexpressing locally advanced or\n             metastatic gastric or GEJ adenocarcinoma.\n\n          -  Previous systemic therapy for locally advanced or metastatic gastric or GEJ or lower\n             esophageal adenocarcinoma.\n\n          -  Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant\n             chemotherapy or chemoradiotherapy to randomization.\n\n          -  Squamous cell histology."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137343", 
            "org_study_id": "20120142"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rilotumumab", 
                "description": "1) Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells. 2) Drug Cisplatin: A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). 3) Drug Capecitabine: A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.", 
                "intervention_name": "Rilotumumab plus CX", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rilotumumab-placebo", 
                "description": "1) Placebo 2) Drug Cisplatin: A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). 3) Drug Capecitabine: A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.", 
                "intervention_name": "Rilotumumab-placebo plus CX", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Cisplatin", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastric Cancer", 
            "First Line Treatment Gastroesophageal Junction (GEJ)", 
            "Gastroesophageal Junction Cancer (GEJ)", 
            "GEJ Cancer"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Kitaadachi-gun", 
                    "country": "Japan", 
                    "state": "Saitama", 
                    "zip": "362-0806"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "China: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine if the treatment of rilotumumab in combination with CX significantly improves progression-free survival as compared with rilotumumab-placebo in combination with CX in subjects with unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma with MET-positive expression.", 
                "measure": "Progression-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "To determine if the treatment of rilotumumab in combination with CX significantly improves overall survival as compared with rilotumumab-placebo in combination with CX in subjects with unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma with MET-positive expression.", 
                "measure": "Overall Survival", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137343"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to Progression (TTP)", 
                "measure": "TTP", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Objective Response Rate", 
                "measure": "ORR", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Disease Control Rate", 
                "measure": "DCR", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Time to Response", 
                "measure": "TTR", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Adverse events and laboratory abnormalities are reported by Common Terminology Criteria for Adverse Events (CTCAE) (v3.0)", 
                "measure": "Incidence of subject adverse events, laboratory abnormalities and immunogenicity", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}